Min Hee Hong

6.5k total citations
242 papers, 3.9k citations indexed

About

Min Hee Hong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Min Hee Hong has authored 242 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Oncology, 103 papers in Pulmonary and Respiratory Medicine and 48 papers in Molecular Biology. Recurrent topics in Min Hee Hong's work include Lung Cancer Treatments and Mutations (83 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Research Studies (32 papers). Min Hee Hong is often cited by papers focused on Lung Cancer Treatments and Mutations (83 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Research Studies (32 papers). Min Hee Hong collaborates with scholars based in South Korea, United States and China. Min Hee Hong's co-authors include Hye Ryun Kim, Byoung Chul Cho, Hyung‐Ho Park, Kyoung‐Ho Pyo, Hyo Sup Shim, Beung‐Chul Ahn, Sang‐Jun Ha, Sung Yong Park, Mi Ran Yun and Hong In Yoon and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Min Hee Hong

215 papers receiving 3.9k citations

Peers

Min Hee Hong
Tatsuya Oda Japan
Chung‐Han Lee United States
Fei Li China
Bora Lim United States
Luitpold Distel Germany
Kwanghee Kim United States
Yifan Wang China
Ying Jing China
Jiang Long China
Michael Meister Germany
Tatsuya Oda Japan
Min Hee Hong
Citations per year, relative to Min Hee Hong Min Hee Hong (= 1×) peers Tatsuya Oda

Countries citing papers authored by Min Hee Hong

Since Specialization
Citations

This map shows the geographic impact of Min Hee Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min Hee Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min Hee Hong more than expected).

Fields of papers citing papers by Min Hee Hong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Min Hee Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min Hee Hong. The network helps show where Min Hee Hong may publish in the future.

Co-authorship network of co-authors of Min Hee Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Min Hee Hong. A scholar is included among the top collaborators of Min Hee Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Min Hee Hong. Min Hee Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hong, Min Hee, Gamin Kim, Yoon Woo Koh, et al.. (2025). Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses. Cancer Communications. 45(9). 1194–1199. 2 indexed citations
2.
Xu, Jiangtao, Jing Wen, Xiaobo Ji, et al.. (2025). Preclinical development of a high affinity anti-exatecan monoclonal antibody and application in bioanalysis of antibody-exatecan conjugates. Journal of Pharmaceutical and Biomedical Analysis. 262. 116843–116843. 1 indexed citations
3.
Sim, Nam Suk, Gamin Kim, Dahee Kim, et al.. (2025). 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy. Cell Reports Medicine. 6(10). 102408–102408.
4.
Kim, Yong Joon, Myeongjee Lee, Eun Hwa Kim, et al.. (2024). Real-world incidences and risk factors of immune-related adverse events in patients treated with immune checkpoint inhibitors: A nationwide retrospective cohort study. Cancer Letters. 596. 216998–216998. 6 indexed citations
5.
Falchook, Gerald S., Patricia LoRusso, Jonathan W. Goldman, et al.. (2024). Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4-1BB, in advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2529–2529. 4 indexed citations
6.
Lim, Sun Min, et al.. (2024). Real-world outcomes with lurbinectedin in second-line and beyond for small cell lung cancer in Korea.. Journal of Clinical Oncology. 42(23_suppl). 211–211.
7.
8.
Hong, Moonki, Sang Wook Lee, Byoung Chul Cho, et al.. (2024). Multiplex analysis for the identification of plasma protein biomarkers for predicting lung cancer immunotherapy response. Therapeutic Advances in Medical Oncology. 16. 12698954–12698954.
9.
Yong, Seung Hyun, Sang Hoon Lee, Hye Ryun Kim, et al.. (2023). Usefulness of bronchial washing fluid for detection of EGFR mutations in non-small cell lung cancer. Lung Cancer. 186. 107390–107390. 2 indexed citations
10.
Lee, Jii Bum, Hyung Soon Park, Su Jin Choi, et al.. (2022). Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. Therapeutic Advances in Medical Oncology. 14. 4287553793–4287553793. 3 indexed citations
11.
Jung, Hyun Ae, Keon Uk Park, Sang‐Hee Cho, et al.. (2022). A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17–11). Clinical Cancer Research. 28(19). 4240–4247. 18 indexed citations
12.
Lee, Jiyun, Min Hee Hong, & Byoung Chul Cho. (2022). Lazertinib: on the Way to Its Throne. Yonsei Medical Journal. 63(9). 799–799. 9 indexed citations
13.
14.
Harding, James J., Víctor Moreno, Yung‐Jue Bang, et al.. (2021). Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. Clinical Cancer Research. 27(8). 2168–2178. 116 indexed citations
15.
Yun, Mi Ran, Dong Hwi Kim, Seok‐Young Kim, et al.. (2020). Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 26(13). 3287–3295. 74 indexed citations
16.
Yun, Jiyeon, Min Hee Hong, Seok‐Young Kim, et al.. (2019). YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(8). 2575–2587. 83 indexed citations
17.
Lim, Sun Min, Jae Woo Choi, Min Hee Hong, et al.. (2019). Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. Lung Cancer. 131. 139–146. 26 indexed citations
18.
Park, Ji Soo, et al.. (2019). A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. Lung Cancer. 134. 46–51. 24 indexed citations
19.
Yun, Mi Ran, You Won Lee, Chae Won Park, et al.. (2019). Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer. EMBO Molecular Medicine. 11(12). e10581–e10581. 46 indexed citations
20.
Brown, Bonnie L., et al.. (2000). Characterization of microsatellite loci in the eastern oyster, Crassostrea virginica. Molecular Ecology. 9(12). 2216–2218. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tatsuya Oda Breakdown of academic impact, for papers by Chung‐Han Lee Breakdown of academic impact, for papers by Fei Li Breakdown of academic impact, for papers by Bora Lim Breakdown of academic impact, for papers by Luitpold Distel Breakdown of academic impact, for papers by Kwanghee Kim Breakdown of academic impact, for papers by Yifan Wang Breakdown of academic impact, for papers by Ying Jing Breakdown of academic impact, for papers by Jiang Long Breakdown of academic impact, for papers by Michael Meister
Rankless by CCL
2026